سيريبروليسين 215.2 مجم / مل 5 امبولات

ما هو دواء سيريبروليسين 215.2 مجم / مل 5 امبولات

جرعة دواءسيريبروليسين 215.2 مجم / مل 5 امبولات

يستعمل دواء سيريبروليسين 215.2 مجم / مل 5 امبولاتcerebrolysin 215.2mg/ml i.m./i.v. 5 amps (5ml) cerebral circulatory inhancer cerebral circulatory inhancer

cerebrolysin a peptide preparation produced from purified pig brain proteins may have positive effects on cognitive function in older patients with vascular dementia (vad) according to a new meta-analysis. -cerebrolysin is a mixture of 80% low-molecular-weight peptides and 20% free amino acids. various studies have shown that the agent s multiple effects include promotion of neuroprotection neuroplasticity and neurogenesis. it is approved in many countries for treatment of alzheimer s disease (ad) stroke and/or traumatic brain injury although not in the united states. a cochrane review of cerebrolysin for stroke published in 2010 concluded there was not enough evidence to evaluate its use in stroke and a review of its use in ad is underway the authors note. -

تركيبة دواءسيريبروليسين 215.2 مجم / مل 5 امبولاتcerebrolysin 215.2mg/ml i.m./i.v. 5 amps (5ml)

يتركب هذا الدواء من :cerebrolysin